Efficacy of dehydroepiandrosterone to overcome the effect of ovarian ageing (DITTO): a proof of principle randomised controlled trial protocol by Jayaprakasan, Kannamannadiar et al.
Efﬁcacy of dehydroepiandrosterone to
overcome the effect of ovarian ageing
(DITTO): a proof of principle
randomised controlled trial protocol
Kannamannadiar Jayaprakasan,1,2,3 Amarin Narkwichean,1 Walid E Maalouf,1
Bruce K Campbell1
To cite: Jayaprakasan K,
Narkwichean A, Maalouf WE,
et al. Efficacy of
dehydroepiandrosterone to
overcome the effect of
ovarian ageing (DITTO): a
proof of principle randomised




▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2014-005767).
Received 23 May 2014
Revised 4 September 2014
Accepted 5 September 2014
1Division of Child Health,
Obstetrics and Gynaecology,
School of Medicine, Faculty









3Derby Fertility Unit, Royal







Introduction: Dehydroepiandrosterone (DHEA) has
been proposed to improve pregnancy rates in women
with diminished ovarian reserve undergoing in vitro
fertilisation (IVF) treatment. However, evidence
regarding its efficacy is supported by a limited number
of randomised controlled trials (RCTs). This double-
blinded RCT aims to measure the effect of DHEA
supplementation prior to and during controlled ovarian
hyperstimulation on ovarian response prior to IVF
treatment in women predicted to have poor ovarian
reserve.
Methods and analysis: Sixty women with ovarian
antral follicle count ≤10 and serum anti-Mullerian
hormone ≤5 pmol/L undergoing IVF/intracytoplasmic
sperm injection (ICSI) treatment at the Nurture fertility
clinic, Nottingham will be recruited. They will be
randomised to either receive DHEA capsule 75 mg/day
or placebo for at least 12 weeks before egg collection.
All participants will undergo standard long down
regulation protocol using human menopausal
gonadotropin 300 IU/day. Serum samples and follicular
fluids at the time of egg collection will be collected for
hormonal immunoassays. For ICSI participants,
cumulus cells stripped from oocyte will be collected for
cumulus gene expression analyses regarding oocyte
competence. Microdrops of oocyte culture media
before the time of ICSI will be assessed for glucose,
pyruvate and lactate utilisation. Embryo transfer will be
performed on day 2, 3 or 5 based on the number and
quality of the embryos available. Pregnancy will be
defined as urine pregnancy test positive (biochemical
pregnancy) and 6–8 weeks ultrasound scan with fetal
heart beat (clinical pregnancy) and live birth. It is
planned to perform the molecular and nutritional
fingerprint analyses in batches after finishing the
clinical phase of the study.
Ethics and dissemination: The approval of the study
was granted by the NHS Research Ethics Committee
(Ref number NRES 12/EM/0002), the Medicines and
Healthcare products Regulatory Agency (MHRA), and
the Nottingham University Hospitals Trust Research and
Development department. All participants shall provide
written informed consent before being randomised into
allocated treatment groups.
Trial registration number: Protocol V.2.0; EudraCT
number: 2011-002425-21; http://www.clinicaltrials.gov;
NCT01572025; CTA reference: 03057/0053/001-0002
INTRODUCTION
One of the major changes in the societies
noted worldwide over the past few decades is
postponement of childbearing due to women
pursuing higher education and a successful
career. Currently, large numbers of women
defer attempting to conceive until their
mid-30s or 40s.1 For instance, in the UK, there
has been a rise in childlessness at the age of
35 from 12% for those born in 1941 to 25%
for those born in 1971.2 An important issue
that has arisen consequently from this trend is
the marked increase in the incidence of
women with infertility who seek medical inter-
ventions to overcome the involuntary childless-
ness incurred as a result of ovarian ageing.
Ovarian ageing, dictated by a decline in
the quantity and quality of oocytes within the
ovaries,3 4 is responsible for the well-
established observation of age-related decline
Strengths and limitations of this study
▪ The study is a double-blinded placebo-controlled
randomised controlled trial. Randomisation
numbers will be generated by the computer
system, and therefore the patient and the health-
care team will not know which treatment (dehy-
droepiandrosterone (DHEA) or placebo) the
patient receives.
▪ The authors also plan to use molecular studies
of the cumulus gene expression and media nutri-
tional fingerprint to elucidate the mechanism of
DHEA on the oocyte development.
▪ As this is a pilot study, the intended sample size
is small and plans to recruit only 60 participants.
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in fertility5–8 and of age-related increase in adverse
reproductive events such as miscarriages9 10 and aneu-
ploid pregnancies.11–13 While the age-related decline in
fertility cannot be overcome with conventional in vitro
fertilisation (IVF) treatment, reduced ovarian reserve
secondary to ovarian ageing is one of the major factors
determining the success of IVF outcome. Further, loss of
ovarian function can have additional health conse-
quences through effects on metabolism, cardiovascular
function, cognition, response to stress, bone strength14–
16 and risk of malignancies.17
While chronological age is an important determinant
of ovarian ageing, there is a considerable interindividual
variation in the rate of the ageing process, possibly inﬂu-
enced by genetic and environmental factors. The pace
at which ovarian ageing occurs is determined by the rate
of primordial follicle initiation, the rate of follicle turn-
over or loss and the rate of follicle and oocyte matur-
ation.18 19 These processes are regulated by
intrafollicular and interfollicular interactions mediated
by pituitary derived gonadotropins and oocytes and
somatic cell-derived local growth regulators, which may
be liable to therapeutic manipulation with drugs such as
dehydroepiandrosterone (DHEA).
DHEA is a weak androgenic steroid secreted mainly
from the adrenal glands but also from ovaries and by
peripheral conversion. The serum levels of DHEA
decline markedly with advancing age. It has been pro-
posed that the oral administration of DHEA in women
may have antiageing effects and improve well-being and
sexual function. A few observational studies reported
that DHEA improves ovarian response and pregnancy
rates in women with reduced ovarian reserve following
assisted reproduction treatment (ART).20–26 In one of
the only three randomised controlled trials (RCTs) pub-
lished so far, a group of 33 women with reduced ovarian
reserve were randomised to receive either 75 mg DHEA
per day orally for at least 6 weeks before starting the ﬁrst
cycle of ovulation induction or no pretreatment.
Participants who did not conceive and continued to the
second cycle took DHEA for at least 16 weeks, while the
average duration of DHEA intake by the study group was
13.5 weeks. While there was no signiﬁcant difference in
terms of mean number of retrieved oocytes and fertilisa-
tion rates, the cumulative live birth rates over two IVF
cycles (23.1% vs 4%; p=0.05) were signiﬁcantly higher in
the DHEA group compared with the control group.26 It
was suggested that the beneﬁt of DHEA treatment
would be most effective if it was supplemented for at
least 3 months, which is equal to the time needed to
affect the gonadotropin-responsive follicle pool.
Therefore, they believed that DHEA acts in ovarian
recruitment and early folliculogenesis.27 However, there
were few methodological issues with that trial. It was not
blinded. It was registered at the ClinicalTrials.gov as con-
trolled clinical trial (CCT) on 3 May 2010 after the trial
was completed in July 2009, in fact after the trial report
had been submitted for publication in February 2012.
The authors freely admitted that they had no prespeci-
ﬁed sample size or primary end point, and were inspect-
ing the results as data accumulated and stopped when
they achieved a nominally signiﬁcant difference in preg-
nancy rate.
While subsequent RCTs failed to demonstrate signiﬁ-
cant improvement after DHEA supplementation,28 29
the other controlled studies reported in the literature so
far suggest that DHEA may improve quantitative and
qualitative ovarian response. It is important to note the
weak methods as they were not blinded and employed
only small sample sizes.30 Further investigation into the
role of DHEA on ovarian ageing is required and women
undergoing ART provide an ideal model with whom we
can evaluate the developmental competence of oocytes
both in vivo and in vitro. Hence, this warrants a well-
designed and large RCT to examine the effect of DHEA
in women with diminished ovarian reserve undergoing
ART treatments. While there are many ovarian reserve
tests with varying predictive abilities reported, antral fol-
licle count (AFC) and anti-Mullerian hormone (AMH)
have consistently been found to have the best diagnostic
accuracy to predict poor ovarian reserve.31
We are proposing a pilot randomised, double-blinded,
placebo controlled trial to examine the feasibility of con-
ducting a large trial, in addition to exploring the effect
of DHEA on oocyte quantity and quality. The principal
objective of this study is to evaluate the effect of DHEA
on the ovarian response to gonadotropins (oocyte quan-
tity) during controlled ovarian stimulation and the
developmental competence of oocytes (oocyte quality)
by using molecular and clinical markers in women with
aged ovaries, identiﬁed by using reported AFC and
AMH thresholds.32–34
MATERIALS AND METHODS
Design, setting and participants
This study is planned as a double-blind, placebo-
controlled, randomised pilot trial, being conducted at a
university-based tertiary fertility centre (Nottingham
University Research and Treatment Unit in
Reproduction (NURTURE), University of Nottingham,
UK). An expected number of 60 patients undergoing
either IVF or intracytoplasmic sperm injection (ICSI)
and predicted to have poor ovarian response will be
recruited to this RCT. The study participants will receive
oral capsules of either 75 mg of DHEA or placebo for at
least 12 weeks before starting ovarian stimulation with
gonadotropin during IVF/ICSI treatment. Participants
will be provided with a maximum 20-week supply of
medication. A DHEA capsule is made from active 75 mg
DHEA powder encapsulated in the white gelatine
capsule by the licensed pharmaceutical company
authorised by the Medicines and Healthcare products
Regulatory Agency (MHRA). Placebo is also produced
from the capsule with similar size, colour and appear-
ance but without the DHEA powder.
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Inclusion criteria
1. Women aged 23–43 years with diminished ovarian
reserve (predicted to be poor responders), deﬁned
as AFC scan ≤10 and/or serum AMH ≤5 pmol/L
undergoing IVF or ICSI treatment.
2. Women must have a regular spontaneous menstrual
cycle of 21–35 days.
3. Women must be willing and comply with scheduled
visits, the treatment plan and laboratory tests and
give written informed consent.
Exclusion criteria
1. Women with body mass index >35 kg/m2;
2. Women with a single ovary;
3. Women with untreated hydrosalpinx/submucous
ﬁbroid/endometrial polyp at the start of treatment;
4. Women with any history of seizure disorders;
5. Women with previous participation in this trial in an
earlier treatment cycle;
6. Women with any known endocrine disorders such as
congenital adrenal hyperplasia, thyroid diseases,
hyperprolactinaemia;
7. Known allergy to DHEA;
8. Diabetic women on insulin, as insulin lessens the
DHEA levels and might reduce the effectiveness of
DHEA supplements.
Recruitment and randomisation
At the initial visit, women seeking IVF/ICSI treatment
will undergo an ultrasound scan for AFC as well as an
AMH blood test. If a woman fulﬁls the eligibility criteria,
she will be invited to participate in this study. After
written signed consent is obtained, participants will be
randomised to receive oral capsules of either 75 mg
DHEA or placebo (once daily) for at least 12 weeks (12–
20 weeks) before starting ovarian stimulation and contin-
ued through stimulation until the day before egg collec-
tion (ﬁgure 1). The randomisation will be based on a
computer-generated pseudo-random code using random
permuted blocks of randomly varying size, created by the
University of Nottingham Clinical Trials Unit (CTU). The
randomisation will be stratiﬁed by age. At randomisation,
the computer will then issue a trial number, which will be
the unique identiﬁer for the trial participant. The corre-
sponding treatment allocation will be transmitted to the
unblinded pharmacy staff, who will dispense the allocated
treatment (trial medication or placebo) to the
participant.
The randomisation code will be maintained by the
CTU. The pharmacy will have the list of participants
with their allocated treatment. The code will be broken
only if any participants develop a serious adverse event,
in which case the chief investigator will be notiﬁed.
Primary objectives
This study aims to evaluate the hypothesis that DHEA
supplementation for at least 12 weeks prior to and
during controlled ovarian hyperstimulation in patients
predicted to be poor responders increases the oocyte
quantity (number of oocytes retrieved). The feasibility of
conducting a large trial is also to be assessed by evaluat-
ing the recruitment rates and compliance of the
recruited participants with DHEA/placebo intake and
follow-up rates.
Figure 1 Participant flow diagram (IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; DHEA,
dehydroepiandrosterone).
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Secondary objectives
Oocyte quality will be determined by expressions of estab-
lished molecular markers. The expression levels of
various cumulus markers including gonadotropin recep-
tors, pentraxin 3, cyclooxygenase 2, hyaluronan synthase
2, bone morphogenetic protein (BMP) antagonist—
gremlin and epidermal growth factor-like signalling mole-
cules will be measured to deﬁne oocyte developmental
competence using real-time PCR. Nutritional ﬁngerprint-
ing by measuring glucose, pyruvate and lactate utilisation
as the energy consumption from the oocyte culture
media will be evaluated to assess the developmental com-
petence of the fertilised oocytes. Finally, we will also be
assessing aneuploidy rates in immature oocytes to see any
beneﬁcial effect of DHEA on oocyte quality. Biochemical
(positive urine human chorionic gonadotropin (hCG) at
2 weeks following embryo transfer) and clinical (viable
pregnancy on ultrasound at 5 weeks following embryo
transfer) pregnancy rates will also be reported as second-
ary outcomes. However, the present study is underpow-
ered to measure plausible effect sizes.
Procedure
All participants will undergo a standard long downregu-
lation protocol (ﬁgure 2) starting with the GnRH
agonist, either nafarelin (Synarel; Pharmacia, UK) or
buserelin (Aventis Pharma, Kent, UK), 7 days earlier
than the expected ﬁrst date of the next menstrual cycle.
Pituitary downregulation will be conﬁrmed by both a
transvaginal ultrasound scan (quiescent ovaries with fol-
licles <10 mm diameter, endometrium ≤5 mm in thick-
ness) and serum oestradiol (<200 pmol/L) on day 2
after the ﬁrst day of the menstruation period. A sample
of serum from the downregulation blood sample will be
stored for serum DHEA and AMH estimation. On con-
ﬁrmation of downregulation, ovarian stimulation will be
started with Human Menopausal Gonadotropin (HMG,
Menopur, Ferring, UK) 300 IU daily by subcutaneous
injection. From day 8 of stimulation, participants will be
monitored for their ovarian response using transvaginal
ultrasound and serum oestradiol levels. Once they meet
the criteria for oocyte retrieval (≥3 leading follicles are
≥17 mm), 10 000 IU of hCG, Pregnyl (Organon
Laboratories Ltd, Cambs, UK) will be administered sub-
cutaneously to trigger oocyte maturation. The trial inter-
vention, gonadotropin injections and GnRH agonist will
be continued until hCG administration. Thirty-six hours
following HCG administration, oocyte retrieval from
ovarian follicles will be performed (ﬁgure 2).
Extra blood samples of serum DHEA and AMH con-
centrations will be collected on the day of egg collec-
tion. Conventional insemination (IVF) or ICSI treatment
will be appropriately selected for individual patients by
embryologists depending on the partner’s semen ana-
lysis and previous treatment history. Prior to ICSI, the
oocytes will be denuded prior to sperm injection accord-
ing to standard clinical practices. Expression levels of a
panel of nine cumulus markers of oocyte competence as
aforementioned will be quantiﬁed by real-time PCR in
cumulus cells removed from one cumulus oocyte
complex (COC)/patient. The metaphase II oocytes
from these selected COCs will be inseminated according
to standard clinical practices. We estimate that the ICSI
treatment rate will be approximately 50% of total
patients, and thus will be able to have cumulus markers
data from about 30 patients. Microdrop culture will be
used to track individual zygotes throughout embryo
development in vitro, until transfer on day 2, 3 to 5 or
cryopreservation. Oocyte developmental competence
will then be assessed indirectly by measuring glucose
(G), pyruvate (P) and lactate (L) utilisation from the
culture media as the energy consumption by the oocyte
from the medium (‘nutritional ﬁnger printing’) will vary
depending on its ability to develop to the blastocyst
stage. The ﬂuid within the follicle from which the above
oocytes are collected will be stored and analysed for
Figure 2 IVF/ICSI treatment protocol used in the study (IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; DHEA,
dehydroepiandrosterone; hCG, human chorionic gonadotropin).
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DHEA levels. Chromosomal assessment of the immature
oocytes recovered at denudation while doing ICSI will
be performed by using comparative genomic hybridisa-
tion. Participants will be reassured that the oocytes that
are utilised for the research would have no further role
in their treatment; therefore, taking part in the study
would not affect their treatment outcome.
Embryo transfer is performed 2, 3 or 5 days following
the day of egg collection, based on the number and
quality of embryos available. One or two embryos will be
transferred depending on the embryo quality and
couple preference. The maximum number of embryos
transferred will be two as per the Human Fertilisation
and Embryology Authority (HFEA) regulations. The
couples will be advised by the embryologists regarding
blastocyst culture and transfer if there are ≥4 fertilised
oocytes at fertilisation check. Couples will be advised for
single embryo transfer if top quality blastocysts are avail-
able for transfer. All women undergoing IVF treatment
will be advised to self-administer progesterone pessaries
(Cyclogest; Alpharma, UK) 400 mg twice daily starting
on the second day after egg collection until the day of
the pregnancy test, which will then be continued until
8 weeks of pregnancy if the treatment is successful. A
urine pregnancy test will be performed approximately
14 days from the day of embryo transfer. All women
having IVF/ICSI treatment will have an early pregnancy
scan at around 7 weeks of gestation (clinical pregnancy;
ﬁgure 2). All the stimulation and outcome data will be
collected and recorded on to the database. Side effects
reported by women will be recorded.
The project will be performed over a period of 2 years
and the last follow-up visit of the participants will be the
day of the ﬁrst early pregnancy scans. While we are plan-
ning to do the molecular analysis and chromosomal ana-
lysis during the last phase of the trial, we will
prospectively collect the baseline and clinical outcome
data as participants go through the trial and undergo
IVF treatment.
Statistical analysis
The trial is designed to test the ‘proof of principle’ that
DHEA priming improves the ovarian response to supero-
vulation. The primary outcome is the total number of
oocytes retrieved. Only the ﬁrst cycle of treatment fol-
lowing randomisation will be analysed. If treatment
cycles are cancelled during the stimulation phase due to
poor ovarian response or if no eggs are retrieved at egg
collection, the number of eggs collected will be
recorded as zero. All participants will be advised to use a
barrier contraception while taking trial medications.
However, if participants spontaneously conceive during
DHEA/placebo treatment, for the primary analysis we
will assign the number of the patient’s oocyte count with
the highest observed number in the rest of the study
while this patient will be included into the positive preg-
nancy outcome group for secondary (pregnancy)
outcome analysis. The secondary outcome will include
(1) biochemical/clinical pregnancy rates, (2) live birth
rates, (3) relative quotients of nine cumulus gene
expressions using real-time PCR, (4) rates of glucose,
pyruvate and lactate consumption, (5) rates of aneu-
ploidy in immature oocytes, (6) serum oestradiol on
hCG day and (7) serum AMH on the sample collected
at egg collection (after treatment).
As this is a pilot study, we estimated the sample size
based on the number of participants that we could
recruit over a period of 18 months. We anticipate
approximately 600 women undergoing IVF/ICSI treat-
ment at NURTURE over an 18-month period.
Considering 20% as our predicted poor responders
based on the inclusion criteria and 50% recruitment
rate, we will be able to recruit 60 participant during the
study period. We anticipate that the size of the effect on
the primary outcome based on the data generated from
this trial will enable us to estimate the sample size for a
large multicentre trial.
Statistical analysis will be performed by using the
Statistical Package for the Social Sciences (SPSS,
Chicago, Illinois, USA). Assuming that the oocyte
numbers in a study population are usually not normally
distributed, the difference in the primary outcome
between groups will be tested using the Mann-Whitney
U test. A two-tailed p value of <0.05 will be taken to indi-
cate statistical signiﬁcance. Analyses will be performed
between the study and control participants who have
complied with the trial as per protocol and not just on
the intention to treat basis.
Ethics and dissemination
The side effects associated with the proposed dose of
DHEA are rare. The published cohort studies and the
RCT have not reported any signiﬁcant adverse or andro-
genic side effects.20–23 26 However, the potential side
effects are related to androgenic effects, and these
include acne, facial hair growth and rarely a deepening
of the voice.35 If women report any of these side effects,
they will be advised to discontinue the trial medication.
The notes of all pregnant participants will be retrospect-
ively reviewed to ensure the normality of the children
born.
This study has received appropriate approval from the
NHS Research Ethics Committee (East Midlands-Derby1
ethics committee; Ref number NRES 12/EM/0002), the
Medicines and Healthcare products Regulatory Agency
(MHRA) for use of investigational medicinal products,
and the Nottingham University Hospitals Trust Research
and Development department. It is being conducted in
accordance with the good clinical practice (GCP) princi-
ples, the ethical principles that are in agreement with
the Declaration of Helsinki 1996, the Medicines for
Human Use Regulations, Statutory Instrument 2004, and
all involved UK laws and regulations. All participants
shall provide written informed consent before being ran-
domised into allocated treatment groups. The
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participants will be informed which treatment they
received after the trial is completed.
We are planning to disseminate the study through
peer-reviewed journal publications and scientiﬁc confer-
ences. The data that will be produced from this research
will have the potential to inﬂuence clinical practice in
fertility clinics worldwide. If the planned intervention is
found to be effective, it provides a low cost, safe and
easily administrable therapy for ovarian ageing.
Furthermore, the overall results will give us more appre-
ciation in understanding the underlying mechanisms of
how DHEA combats reproductive ageing. This provides
a mechanistic framework for translational research on
mechanisms of ovarian ageing and drug interventions to
slow down the ovarian ageing process and subsequent
adverse consequences.
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